• Memphasys signs exclusive three-year agreement with IVF Envimed for Felix system distribution in Thailand
• Initial order of 100 Felix cartridges and 3 consoles received
• Expected revenue of approximately A$430,500 over three years
• Thailand agreement boosts total South-East Asian revenue to A$1.0M

Memphasys Limited (ASX: MEM) has executed an exclusive three-year commercial distribution agreement with IVF Envimed Co., Ltd. for the sale and distribution of the Felix sperm separation system across Thailand. The agreement, which is the Company's second commercial distribution partnership in South-East Asia, is worth a minimum value approaching A$1.0 million over the contract life and delivers meaningful commercialization coverage across two of South-East Asia's most active IVF markets. Total contracted sales for FY2026 have now reached approximately A$3.0M, exceeding the stated corporate goal of A$2.0M. The agreement is structured as an exclusive three-year arrangement commencing on the Trigger Date, defined as the date on which Thai FDA / Medical Device Control Division regulatory approval is received for the commercial sale and distribution of the Felix System. Memphasys anticipates Thai FDA approval within approximately three to six months.

Minimum contracted value of approximately A$430,500 over three years

Memphasys will progress the Thai FDA regulatory approval process alongside IVF Envimed, with commercial revenues targeted to commence within approximately three to six months.